Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$5,200,000.00
COVID-19 Vaccine: Phase 2 clinical trial of DNA-based vaccine Covigenix VAX-001
FY 2021-22 · 2021-11-01
Summary
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 2 clinical trials to establish its safety and immunogenicity in healthy adults.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-11-01 | 2021-22 | $5,200,000.00 |
| 1 | 2021-11-01 | 2021-22 | $5,200,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 275 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 275 jours.
Agreement End Date
2022-12-31
Agreement Number
981653
Agreement Start Date
2021-11-01
Agreement Title
COVID-19 Vaccine: Phase 2 clinical trial of DNA-based vaccine Covigenix VAX-001
Agreement Title (French)
Vaccin contre la COVID-19 : Essai clinique de phase 2 du vaccin à base d'ADN Covigenix VAX-001
Agreement Type
Contribution
Agreement Value
$5,200,000.00
Amendment Date
2022-03-25
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 2 clinical trials to establish its safety and immunogenicity in healthy adults.
Description (French)
Entos a développé le Covigenix VAX-001, un vaccin ADN à véhicule protéo-lipidique (VPL) destiné à la prévention de l'infection de la COVID-19 par le SRAS-CoV-2. Dans le cadre de ce projet, Entos fera progresser le candidat vaccin VAX-001 jusqu'aux essais cliniques de phase 2. Le but est d'établir son innocuité et son immunogénicité chez des adultes en bonne santé.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2021-2022-Q3-981653
